These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 11880505)

  • 1. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
    Wu DC; Jackson-Lewis V; Vila M; Tieu K; Teismann P; Vadseth C; Choi DK; Ischiropoulos H; Przedborski S
    J Neurosci; 2002 Mar; 22(5):1763-71. PubMed ID: 11880505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.
    Du Y; Ma Z; Lin S; Dodel RC; Gao F; Bales KR; Triarhou LC; Chernet E; Perry KW; Nelson DL; Luecke S; Phebus LA; Bymaster FP; Paul SM
    Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14669-74. PubMed ID: 11724929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
    Moon M; Kim HG; Hwang L; Seo JH; Kim S; Hwang S; Kim S; Lee D; Chung H; Oh MS; Lee KT; Park S
    Neurotox Res; 2009 May; 15(4):332-47. PubMed ID: 19384567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
    Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
    J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
    Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
    J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha.
    Sriram K; Miller DB; O'Callaghan JP
    J Neurochem; 2006 Feb; 96(3):706-18. PubMed ID: 16405514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minocycline enhances MPTP toxicity to dopaminergic neurons.
    Yang L; Sugama S; Chirichigno JW; Gregorio J; Lorenzl S; Shin DH; Browne SE; Shimizu Y; Joh TH; Beal MF; Albers DS
    J Neurosci Res; 2003 Oct; 74(2):278-85. PubMed ID: 14515357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Furuya T; Hayakawa H; Yamada M; Yoshimi K; Hisahara S; Miura M; Mizuno Y; Mochizuki H
    J Neurosci; 2004 Feb; 24(8):1865-72. PubMed ID: 14985426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation.
    Chung YC; Kim SR; Park JY; Chung ES; Park KW; Won SY; Bok E; Jin M; Park ES; Yoon SH; Ko HW; Kim YS; Jin BK
    Neuropharmacology; 2011 May; 60(6):963-74. PubMed ID: 21288472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of nitric oxide synthase against MPTP neurotoxicity in mice.
    Kurosaki R; Muramatsu Y; Michimata M; Matsubara M; Kato H; Imai Y; Itoyama Y; Araki T
    Neurol Res; 2002 Oct; 24(7):655-62. PubMed ID: 12392201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
    Yokoyama H; Takagi S; Watanabe Y; Kato H; Araki T
    J Neural Transm (Vienna); 2008 Jun; 115(6):831-42. PubMed ID: 18235988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
    Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
    J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation.
    Chung YC; Bok E; Huh SH; Park JY; Yoon SH; Kim SR; Kim YS; Maeng S; Park SH; Jin BK
    J Immunol; 2011 Dec; 187(12):6508-17. PubMed ID: 22079984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
    Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
    Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
    Kim S; Moon M; Park S
    J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial impairment and melatonin protection in parkinsonian mice do not depend of inducible or neuronal nitric oxide synthases.
    López A; Ortiz F; Doerrier C; Venegas C; Fernández-Ortiz M; Aranda P; Díaz-Casado ME; Fernández-Gil B; Barriocanal-Casado E; Escames G; López LC; Acuña-Castroviejo D
    PLoS One; 2017; 12(8):e0183090. PubMed ID: 28800639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.
    Zhang W; Wang T; Qin L; Gao HM; Wilson B; Ali SF; Zhang W; Hong JS; Liu B
    FASEB J; 2004 Mar; 18(3):589-91. PubMed ID: 14734632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.
    Delgado M; Ganea D
    FASEB J; 2003 May; 17(8):944-6. PubMed ID: 12626429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice.
    Liu J; Wang MW; Gu P; Ma QY; Wang YY; Geng Y; Yuan ZY; Cui DS; Zhang ZX; Ma L; Zhang BH; Zhou MG; Zhu AP
    Brain Res; 2010 Jul; 1345():213-20. PubMed ID: 20546706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.